High miR-659-3p miR-659-3p miR-659-3phexpressions with responsive distinguishedlete or patientsresponse) from patients with stable disease.
Eleven of twelve evaluable patients (or 11 of 19 total patients) had responsive disease, including two complete remissions and nine partial remissions, for an overall response rate of 91% for evaluable patients and 58% for all patients (95% confidence intervals from 60% to 99% and 36% to 77%, respectively).
The altered expression patterns observed for the six circulating miRs separated patients with resistant disease from those with drug responsive disease.
And, even though it has not yet been investigated in a model of castration-resistant disease, it could potentially be useful in CPRC patients as well as in patients undergoing treatment for disseminated androgen responsive disease.
Main outcome measures used were the Seattle Angina Questionnaire, a valid, reliable, and responsive disease-specific functional status measure for patients with coronary disease, and the Mental Health Inventory, a mental health screening instrument from the Short Form-36.
The 3-month change in scores for the Seattle Angina Questionnaire, a valid, reliable, and responsive disease-specific health status measure for patients with coronary disease, was used as the main outcome measure.
Patients were randomized by center to placebo (16 patients, 31%), oral bexarotene 300 mg/m2/day (21 patients, 40%), or oral bexarotene 600 mg/m2/day (15 patients, 29%) following demonstration of stable or responsive disease after first-line chemotherapy.
This study shows that patients can tolerate bexarotene at initial doses up to 600 mg/m2/dafterter platinum-based chemotherapy and that bexarotene may have the potential to delay disease progression in patients with advanced non small-cell lunon small-cell previouslungtable or responsive disease following platinum-based cancerherapy.
Biomarkers are needed to predict responsive disease.
As shown in Table 1, about 60% of the patients had endocrine responsive disease.
